

GLP-1 Pipeline Update: February 2026

As the GLP-1 pipeline expands, Prime Therapeutics continually monitors this evolving landscape to provide a clear, credible snapshot of what is on the horizon. The table below highlights the earliest potential approval dates for each agent. Dates are based on manufacturer announcements or communications, or are projected using study completion timelines, and may change as new information becomes available.

Drug / dosage form	Diabetes & diabetes-related conditions				Obesity or overweight & related conditions							Other
	T2DM	T2DM + CVD	T2DM + PAD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	CLBP + obesity or overweight	HTN + obesity or overweight	OSA + obesity or overweight	OA of knee + obesity or overweight	T1DM ± obesity or overweight	MASH
Amgen												
maridebart cafraglutide / SC					2028							
AstraZeneca												
exenatide (Byetta/Bydureon Bcise) / SC	FDA-approved (Byetta only ages ≥ 10 years)											
Eli Lilly												
dulaglutide (Trulicity) / SC	FDA-approved (ages ≥ 10 years)	FDA-approved										
tirzepatide (Mounjaro) / SC	FDA-approved (ages ≥ 10 years)	FDA decision mid-2026									2028	
tirzepatide (Zepbound) / SC					FDA-approved				FDA-approved			
orforglipron / oral	2027				FDA decision 2Q 2026			2028	2026			
retatrutide / SC	2027				2027	2027	2028		2027	2027		
Novo Nordisk												
liraglutide (Victoza)* / SC	FDA-approved (ages ≥ 10 years)	FDA-approved										
liraglutide (Saxenda) / SC					FDA-approved (ages ≥ 12 years)							

Drug / dosage form	Diabetes & diabetes-related conditions				Obesity or overweight & related conditions							Other
	T2DM	T2DM + CVD	T2DM + PAD	Diabetic nephropathy	Obesity or overweight	Obesity or overweight + CVD	CLBP + obesity or overweight	HTN + obesity or overweight	OSA + obesity or overweight	OA of knee + obesity or overweight	T1DM ± obesity or overweight	MASH
Novo Nordisk (cont.)												
liraglutide + insulin degludec (Xultophy) / SC	FDA-approved											
semaglutide (Ozempic) 1.5 mg, 4 mg, 9 mg / oral	FDA-approved	FDA-approved										
semaglutide (Rybelsus) 3 mg, 7 mg, 14 mg / oral	FDA-approved	FDA-approved										
semaglutide 25 mg (Ozempic) / oral	<i>FDA decision 4Q 2026</i>											
semaglutide 25 mg (Wegovy) / oral					FDA-approved	FDA-approved						
semaglutide 1 mg & 2 mg (Ozempic) / SC	FDA-approved	FDA-approved	<i>sNDA withdrawn</i>	FDA-approved								
semaglutide 1.7 mg & 2.4 mg (Wegovy) / SC					FDA-approved (ages ≥ 12 years)	FDA-approved				2027		FDA-approved
semaglutide 7.2 mg (Wegovy) / SC					<i>FDA decision 1Q 2026</i>							
cagrilintide + semaglutide / SC	2027				<i>FDA decision Dec. 2026</i>							
Sanofi												
lixisenatide + insulin glargine (Soliqua) / SC	FDA-approved											
Viking												
VK2735 / SC					2028							
Zealand, Boehringer Ingelheim												
survodutide / SC					2027	2027						2027 (+ obesity)

*generics available

Glossary

CLBP = chronic low back pain

CKD = chronic kidney disease

CVD = cardiovascular disease

FDA = Food and Drug Administration

GLP-1 = glucagon-like peptide-1 receptor agonist

HF = heart failure

HTN = hypertension

MASH = metabolic dysfunction-associated steatohepatitis

OA = osteoarthritis

OSA = obstructive sleep apnea

PAD = peripheral arterial disease

SC = subcutaneous

sNDA = supplemental New Drug Application

T1DM = type 1 diabetes mellitus

T2DM = type 2 diabetes mellitus

Disclaimer

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.

All brand names are property of their respective owners.